Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BR1015 vs Co-administration of Components in Healthy Volunteers
NCT06008028Phase 1Completed
- Sponsor
- Boryung
- Start
- Aug 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fimasartan and indapamide in hypertension (HTN) (2 arms), sponsored by Boryung. Primary endpoints: Area Under the Curve over the dosing interval and Maximum Plasma Concentration. Started Aug 2023; status: completed.
02
Drugs
fimasartanindapamide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06008028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06008028.